Darrow Company’s Quest Diagnostics DGX Stock Holding History

Darrow Company’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-52	Closed	-$6K	–	38
2022 Q2	$6K	Buy	+52	New	+$7.09K	0.01%	68

Other funds holding DGX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Darrow Company's DGX Position: Q3 2022 in Review

Darrow Company sold out of Quest Diagnostics (DGX) in Q3 2022, closing a stake of 52 shares — an estimated $6K sold.

Darrow Company first reported a position in DGX in Q2 2022 and held it in 1 quarter. The position peaked at $6K in Q2 2022. 808 funds tracked by Wall St. Rank hold DGX as of Q3 2022.

Darrow Company reported no remaining Quest Diagnostics position as of Q3 2022 after selling out during the quarter.
Darrow Company sold 52 Quest Diagnostics shares in Q3 2022, an estimated $6K.
Darrow Company first reported a position in Quest Diagnostics in Q2 2022 and held it in 1 quarter.
Darrow Company's Quest Diagnostics position peaked at $6K in Q2 2022.
808 funds tracked by Wall St. Rank held Quest Diagnostics as of Q3 2022.

Based on Darrow Company's 13F filing for Q3 2022, filed 3 Nov 2022.